Wischmann, Hans-Aloys
Logroscino, Giancarlo
Kurth, Tobias
Piccininni, Marco https://orcid.org/0000-0002-1397-0060
Funding for this research was provided by:
Regione Puglia and CNR for Tecnopolo per la Medicina di Precisione (CUPB84I18000540002)
Charité - Universitätsmedizin Berlin
Article History
Received: 19 March 2024
Accepted: 8 July 2024
First Online: 16 July 2024
Declarations
:
: Hans-Aloys Wischmann worked for Philips in various healthcare research and innovation management roles, up to April 2021. Outside of the submitted work, Giancarlo Logroscino reports having received speaking honoraria from Lilly, GE Healthcare, Lundbeck and being an associate editor of Neuroepidemiology/Karger. Outside of the submitted work, Tobias Kurth reports receiving research grants from the Gemeinsamer Bundesausschuss (G-BA Federal Joint Committee, Germany) and the Bundesministerium für Gesundheit (BMG—Federal Ministry of Health, Germany). He further reports having received personal compensation from Eli Lilly and Company, Novartis, the BMJ, and Frontiers. Marco Piccininni reports having received partial funding from Novartis Pharma and being awarded a research grant from the Center for Stroke Research Berlin (private donations), both outside of the submitted work.
: Ethical approval was not required for this research as all analyzed data were simulated based on publicly available statistics, and no human participants were involved.